Amgen Foundation pledges up to $5 million to Hurricane Maria relief efforts
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in Puerto Rico, including financial assistance for shelter, medical attention, clothing and other critical relief.
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
- Details
- Category: Bristol-Myers Squibb
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
- Details
- Category: Novartis
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP),
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
- Details
- Category: Bayer
With approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions.
Pfizer goes to Court to allow competition for biologics and expand options for patients
- Details
- Category: Pfizer
To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) has filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J). The suit alleges that J&J's exclusionary contracts and other anticompetitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of robust price competition in the innovative and growing biologics marketplace for patients.
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'
- Details
- Category: Boehringer Ingelheim
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.(1,2) This year for IPF World Week (16 - 24 September), Boehringer Ingelheim is raising awareness of
Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) announced that Janssen Research & Development LLC (Janssen) are collaborating with the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats.
More Pharma News ...
- Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
- Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology
- More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
- AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
- Merck set to join forces with Project Data Sphere to pioneer Global Oncology Big Data Alliance
- Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
- Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in immuno-oncology